NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Propionic Acid for Multiple Sclerosis: Safety and Benefits

CompletedPhase 2, Phase 3

Sponsor: Salzburger Landeskliniken

Conditions: Multiple Sclerosis

Interventions: Propionic acid 1000 mg capsule

Countries: Austria

The purpose of this study is to explore the long-term safety, tolerability, and clinical efficacy of propionic acid as an add-on therapy in multiple sclerosis (MS).

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of multiple sclerosis (MS)
* Clinically and radiologically stable MS in the previous 3 months
* Age between 18 and 70 years
* Positive finding for oligoclonal bands (OCBs)
* Written consent
* Blood collection at the beginning and end of the study for routine parameter examination as well as sample preservation (especially for measuring propionic acid levels)
* Negative pregnancy test for female participants of childbearing age

Exclusion Criteria:

* History of ongoing propionic acid (PA) supplementation exceeding 3 months
* Positive JC virus titer during natalizumab treatment
* Presence of severe active systemic disease
* Presence of acute neurological conditions

Locations (1)

Salzburg, State of Salzburg, Austria